Processa Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Supplementary Financial Information (unaudited): Schedule of Quarterly Financial Information (Details) (USD $)	12 Months Ended		3 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
Total revenue	$ 200,201us-gaap_Revenues	$ 312,480us-gaap_Revenues
Net loss applicable to common stockholders	(6,029,141)	(3,090,003)
Net loss per common share basic and diluted	$ (0.68)us-gaap_EarningsPerShareBasicAndDiluted	$ (0.61)us-gaap_EarningsPerShareBasicAndDiluted
N2013Member
Total revenue			14,400	52,621	112,835	20,345	70,090	125,910	97,280	19,200
Net (loss)			(1,538,804)	(791,954)	(851,216)	(1,344,276)	(806,925)	(718,840)	(726,571)	(816,365)
Net loss applicable to common stockholders			$ (2,862,126)	$ (871,840)	$ (912,351)	$ (1,382,824)	$ (473,738)	$ (932,600)	$ (768,358)	$ (915,307)
Net loss per common share basic and diluted			$ (0.32)	$ (0.10)	$ (0.11)	$ (0.17)	$ (0.06)	$ (0.12)	$ (0.34)	$ (0.48)